Sanofi said its Genzyme Corp. unit began shipping the Fabrazyme rare-disease medicine from its newly approved plant in Framingham, Massachusetts.

The Paris-based drugmaker reiterated that patients in the U.S. will be able to return to full dosing this month. In Europe, the process of moving the most severely affected patients to full Fabrazyme dosing also begins this month, Sanofi said in an e-mailed statement. Normal supply levels of Fabrazyme will begin in the second quarter and continue throughout the year as planned, the company said.

Sanofi said in January the U.S. Food and Drug Administration’s approval of the plant would help Genzyme eliminate shortages of its medicines Fabrazyme and Cerezyme.

To contact the editor responsible for this story: Albertina Torsoli at atorsoli@bloomberg.net